Ophthotech announced that Genentech will join Novartis and split rights to pegpleranib (Fovista) for the treatment of wet AMD.
Powered by Versicherungsvergleich
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Find an Eye MD near you!
Genentech opts-in for Fovista
- Details